QCG
PVLA

Quadrant Capital Group’s Palvella Therapeutics PVLA Stock Holding History

Quadrant Capital Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$1.25K – 2691
2026
Q1 		$1.25K Hold
10
– – ﹤0.01% 2561
2025
Q4 		$1.05K Hold
10
– – ﹤0.01% 2594
2025
Q3 		$627 Buy
+10
New +$446 ﹤0.01% 2592

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Quadrant Capital Group's PVLA Position: Q2 2026 in Review

Quadrant Capital Group sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 10 shares — an estimated $1.25K sold.

Quadrant Capital Group first reported a position in PVLA in Q3 2025 and held it in 3 quarters. The position peaked at $1.25K in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Quadrant Capital Group reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 10 Palvella Therapeutics shares in Q2 2026, an estimated $1.25K.
  • Quadrant Capital Group first reported a position in Palvella Therapeutics in Q3 2025 and held it in 3 quarters.
  • Quadrant Capital Group's Palvella Therapeutics position peaked at $1.25K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.